| MUSILOVÁ, Milena, Filip RÁZGA, Tomáš JURČEK, Ivana JEŽÍŠKOVÁ, Marek BORSKÝ, Veronika NÉMETHOVÁ, Daniela ŽÁČKOVÁ, Martin ČULEN, Dana DVOŘÁKOVÁ, Jiří MAYER and Zdeněk RÁČIL. BCR-ABL1 kinase domain mutational analysis of CD34+ stem/progenitor cells in newly diagnosed CML patients by next-generation sequencing. American Journal of Hematology. Wiley-Blackwell, 2014, vol. 89, No 10, p. 1016-1017. ISSN 0361-8609. Available from: https://dx.doi.org/10.1002/ajh.23794. |
Other formats:
BibTeX
LaTeX
RIS
@article{1216596,
author = {Musilová, Milena and Rázga, Filip and Jurček, Tomáš and Ježíšková, Ivana and Borský, Marek and Némethová, Veronika and Žáčková, Daniela and Čulen, Martin and Dvořáková, Dana and Mayer, Jiří and Ráčil, Zdeněk},
article_number = {10},
doi = {http://dx.doi.org/10.1002/ajh.23794},
keywords = {BCR-ABL; CD34+; CML; next generation sequencing},
language = {eng},
issn = {0361-8609},
journal = {American Journal of Hematology},
title = {BCR-ABL1 kinase domain mutational analysis of CD34+ stem/progenitor cells in newly diagnosed CML patients by next-generation sequencing},
volume = {89},
year = {2014}
}
TY - JOUR
ID - 1216596
AU - Musilová, Milena - Rázga, Filip - Jurček, Tomáš - Ježíšková, Ivana - Borský, Marek - Némethová, Veronika - Žáčková, Daniela - Čulen, Martin - Dvořáková, Dana - Mayer, Jiří - Ráčil, Zdeněk
PY - 2014
TI - BCR-ABL1 kinase domain mutational analysis of CD34+ stem/progenitor cells in newly diagnosed CML patients by next-generation sequencing
JF - American Journal of Hematology
VL - 89
IS - 10
SP - 1016-1017
EP - 1016-1017
PB - Wiley-Blackwell
SN - 03618609
KW - BCR-ABL
KW - CD34+
KW - CML
KW - next generation sequencing
N2 - Mutations in the BCR-ABL1 kinase domain (KD) represent one of the most important causes of resistance to tyrosine kinase inhibitors (TKIs) treatment in patients with chronic myeloid leukemia (CML). The resistance-causing mutations are hypothesized to expand directly from the stem and/or progenitor cells and are present in CD341 cells significantly earlier than they occur in bone marrow or peripheral blood. Thus, early detection of these mutations is of great importance, since it can affect the subsequent TKI therapy.
ER -
MUSILOVÁ, Milena, Filip RÁZGA, Tomáš JURČEK, Ivana JEŽÍŠKOVÁ, Marek BORSKÝ, Veronika NÉMETHOVÁ, Daniela ŽÁČKOVÁ, Martin ČULEN, Dana DVOŘÁKOVÁ, Jiří MAYER and Zdeněk RÁČIL. BCR-ABL1 kinase domain mutational analysis of CD34+ stem/progenitor cells in newly diagnosed CML patients by next-generation sequencing. \textit{American Journal of Hematology}. Wiley-Blackwell, 2014, vol.~89, No~10, p.~1016-1017. ISSN~0361-8609. Available from: https://dx.doi.org/10.1002/ajh.23794.
|
